Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引：42

作者：

Curigliano, Giuseppe ^{[1
,2
]}

Hu, Xichun ^{[3
]}

Dent, Rebecca Alexandra ^{[4
]}

Yonemori, Kan ^{[5
]}

Barrios Sr, Carlos H. ^{[6
]}

O'Shaughnessy, Joyce ^{[7
]}

Wildiers, Hans ^{[8
]}

Zhang, Qingyuan ^{[9
]}

Im, Seock-Ah ^{[10
]}

Saura, Cristina ^{[11
]}

Biganzoli, Laura ^{[12
]}

Sohn, Joohyuk ^{[13
]}

Levy, Christelle ^{[14
]}

Jacot, William ^{[15
]}

Begbie, Natasha ^{[16
]}

Ke, Jun ^{[17
]}

Patel, Gargi Surendra ^{[18
]}

Bardia, Aditya

机构：

[1] Univ Milan, Milan, Italy

[2] IRCCS, European Inst Oncol, Milan, Italy

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[5] Natl Canc Ctr, Tokyo, Japan

[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil

[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA

[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy

[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[14] Ctr Francois Baclesse, Caen, France

[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France

[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England

[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA

[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.17_suppl.LBA1000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1000

引用

页码：LBA1000 / LBA1000

页数：1

共 50 条

[41] Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002) [J].

Hua, Xin ;

Bi, Xi-Wen ;

Zhao, Jian-Li ;

Shi, Yan-Xia ;

Lin, Ying ;

Wu, Zhi-Yong ;

Zhang, Yuan-Qi ;

Zhang, Le-Hong ;

Zhang, An-Qing ;

Huang, Heng ;

Liu, Xin-Mei ;

Xu, Fei ;

Guo, Ying ;

Xia, Wen ;

Hong, Ruo-Xi ;

Jiang, Kui-Kui ;

Xue, Cong ;

An, Xin ;

Zhong, Yong-Yi ;

Wang, Shu-Sen ;

Huang, Jia-Jia ;

Yuan, Zhong-Yu .

CLINICAL CANCER RESEARCH, 2022, 28 (04) :637-645

[42] Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC) [J].

Swallow, Elyse ;

Wang, Jenny ;

Thomason, Darren ;

Tan, Ruo-Ding ;

Kageleiry, Andrew ;

Signorovitch, James .

CANCER RESEARCH, 2015, 75

[43] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2e) breast cancer (BC): Results from TROPION-Breast01 China cohort [J].

Wang, S. ;

Zhang, Q. ;

Jiang, Z. ;

Tong, Z. ;

Li, W. ;

Wang, J. ;

Ouyang, Q. ;

Yao, T. ;

Wang, Y. ;

Sun, M. L. ;

Wang, X. ;

Wang, S. ;

Zang, A. ;

Zhang, Z. ;

Chen, W. ;

Wang, X. ;

Li, H. ;

Sheng, Y. ;

Bardia, A. ;

Xu, B. .

ANNALS OF ONCOLOGY, 2024, 35 :S1418-S1419

[44] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). [J].

Luis, Ines Maria Vaz Duarte ;

Guo, Hao ;

Barry, William Thomas ;

Krop, Ian E. ;

Wagle, Nikhil ;

Lowe, Alarice ;

Gore, Danielle ;

Andrews, Chelsea ;

Osmani, Wafa ;

Isakoff, Steven J. ;

Tung, Nadine M. ;

Winer, Eric P. ;

Lin, Nancy U. ;

Freedman, Rachel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[45] Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07) [J].

Hamilton, Erika ;

Jhaveri, Komal ;

Loi, Sherene ;

Anders, Carey ;

Schmid, Peter ;

Penkov, Konstantin ;

Artamonova, Elena ;

Zhukova, Lyudmila ;

Stroyakovsky, Daniil L. ;

Doval, Dinesh Chandra ;

Villanueva, Rafael ;

Michelini, Flavia ;

Chandarlapaty, Sarat ;

Wilson, Matt ;

Boston, Sarice R. ;

Konpa, Adam ;

Mondal, Shoubhik ;

Andre, Fabrice .

CANCER RESEARCH, 2023, 83 (05)

[46] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03 [J].

Hurvitz, Sara ;

Kim, Sung-Bae ;

Chung, Wei-Pang ;

Im, Seock-Ah ;

Park, Yeon Hee ;

Hegg, Roberto ;

Kim, Min-Hwan ;

Tseng, Ling-Ming ;

Petry, Vanessa ;

Chung, Chi-Feng ;

Iwata, Hiroji ;

Hamilton, Erika ;

Curigliano, Giuseppe ;

Xu, Binghe ;

Lee, Caleb ;

Liu, Yali ;

Cathcart, Jillian ;

Bako, Emarjola ;

Verma, Sunil ;

Cortes, Javier .

CANCER RESEARCH, 2022, 82 (04)

[47] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). [J].

Slamon, Dennis J. ;

Fasching, Peter A. ;

Patel, Ravindranath ;

Verma, Sunil ;

Hurvitz, Sara A. ;

Chia, Stephen K. L. ;

Crown, John ;

Martin, Miguel ;

Barrios, Carlos H. ;

Spera, Gonzalo ;

Lopez, Celine ;

Hor, Ines ;

Pelov, Diana ;

Hughes, Gareth ;

Nawinne, Moditha ;

Hortobagyi, Gabriel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[48] Trends in the choice of first line treatment for hormone - responsive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study. [J].

D'Alonzo, Alessia ;

Bighin, Claudia ;

Puglisi, Fabio ;

DeLaurentiis, Michelino ;

Fontana, Andrea ;

Pugliese, Palma ;

Arpino, Grazia ;

Poggio, Francesca ;

Vaglica, Marina ;

Dellepiane, Chiara ;

Blondeaux, Eva ;

Conte, Benedetta ;

Cognetti, Francesco ;

Garrone, Ornella ;

Pastorino, Simona ;

Ceppi, Marcello ;

Del Mastro, Lucia .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[49] SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype [J].

Ciruelos, E. M. ;

Garcia, A. A. ;

Cortes, J. ;

Pernas Simon, S. ;

Garate, E. ;

Mele, M. ;

Montano, A. ;

Martinez-Janez, N. ;

Oliveira, M. ;

de la Haba-Rodriguez, J. ;

Vega, E. ;

Perello Martorell, A. ;

Bermejo De Las Heras, B. ;

Cantos Sanchez De Ibarguen, B. ;

Martinez, E. ;

Vila Navarro, E. ;

Pascual, T. ;

Gonzalez-Farre, X. ;

Villagrasa, P. ;

Prat, A. .

ANNALS OF ONCOLOGY, 2021, 32 :S77-S77

[50] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2 [J].

Piccart, M. ;

Hortobagyi, G. N. ;

Campone, M. ;

Pritchard, K. I. ;

Noguchi, S. ;

Rugo, H. ;

Gnant, M. ;

Feng, W. ;

Taran, T. ;

Baselga, J. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 :S1-S1

← 1 2 3 4 5 →